ProfileGDS5678 / 1455349_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 94% 96% 95% 96% 95% 94% 94% 94% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.3161295
GSM967853U87-EV human glioblastoma xenograft - Control 28.6558695
GSM967854U87-EV human glioblastoma xenograft - Control 38.2857594
GSM967855U87-EV human glioblastoma xenograft - Control 48.8835496
GSM967856U87-EV human glioblastoma xenograft - Control 58.6284895
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.4479696
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3582595
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.242194
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2283494
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.2140794
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3683895
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.4088395
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.5679595
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.3817295